SLRN250117C10000
- 0.05
- 0.000.00%
Acelyrin Newsroom
ACELYRIN Is Maintained at Neutral by Citigroup
Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3
TD Cowen Maintains Acelyrin(SLRN.US) With Buy Rating
Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $13
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6
ACELYRIN Is Maintained at Neutral by HC Wainwright & Co.
ACELYRIN, INC.'s Lonigutamab Program: Balancing Innovation and Uncertainty With a Hold Rating
Acelyrin Analyst Ratings
Promising Phase 1/2 Results for ACELYRIN's Lonigutamab Support Buy Rating
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5
Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections
ACELYRIN Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
ACELYRIN, INC. (SLRN) Receives a Buy From Piper Sandler
Acelyrin Analyst Ratings
Hold Rating for ACELYRIN, INC. Amid Izokibep Trial Setback and Focus on Lonigutamab Development